PCM
PTCT icon

Penserra Capital Management’s PTC Therapeutics PTCT Stock Holding History

Penserra Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,615
Closed -$60K – 1507
2021
Q3 		$60K Buy
1,615
+10
+0.6% +$411 ﹤0.01% 998
2021
Q2 		$67K Buy
1,605
+15
+0.9% +$643 ﹤0.01% 918
2021
Q1 		$75K Buy
1,590
+25
+2% +$1.49K ﹤0.01% 745
2020
Q4 		$95K Buy
1,565
+987
+171% +$58.2K ﹤0.01% 608
2020
Q3 		$27K Buy
+578
New +$28.5K ﹤0.01% 703

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Penserra Capital Management's PTCT Position: Q4 2021 in Review

Penserra Capital Management sold out of PTC Therapeutics (PTCT) in Q4 2021, closing a stake of 1,615 shares — an estimated $60K sold.

Penserra Capital Management first reported a position in PTCT in Q3 2020 and held it in 5 quarters. The position peaked at $95K in Q4 2020. 178 funds tracked by Wall St. Rank hold PTCT as of Q4 2021.

  • Penserra Capital Management reported no remaining PTC Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,615 PTC Therapeutics shares in Q4 2021, an estimated $60K.
  • Penserra Capital Management first reported a position in PTC Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's PTC Therapeutics position peaked at $95K in Q4 2020.
  • 178 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.